Skip To Main Content
A Subject on Muck Rack

A Subject

As seen in: Associations Now
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to A Subject’s profile

Articles by A Subject

Re: linux-distros list policy and Linux kernel, again

|
By on Mon, A Subject
| seclists.org
oss-sec mailing list archives From: Solar Designer <solar () openwall com> Date: Fri, 8 Sep 2023 19:33:21 +0200 Hi, I've just relaxed the policy on posting exploits.
Open in Who Shared Issue with article?

Re: linux-distros list policy and Linux kernel, again

|
By Willy Tarreau, Hi Alexander, A Subject
| seclists.org
oss-sec mailing list archives From: Willy Tarreau <w () 1wt eu> Date: Mon, 4 Sep 2023 22:14:26 +0200 Hi Alexander, On Wed, Aug 30, 2023 at 05:26:33PM +0200, Solar Designer wrote: I couldn't blame a bug reporter for wanting to have their week-ends and nights again and think everything's behind them and in someone else's hands now. Right.
Open in Who Shared Issue with article?

Re: linux-distros list policy and Linux kernel, again

|
By Hi Willy, on Mon, A Subject
| seclists.org
oss-sec mailing list archives From: Solar Designer <solar () openwall com> Date: Wed, 30 Aug 2023 17:26:33 +0200 Hi Willy, On Mon, Aug 28, 2023 at 09:17:56PM +0200, Willy Tarreau wrote: what I suspect instead is that reporting security issues is so stressful for anyone (constantly making sure not to do a mistake nor to send to the wrong people) that once they see the fix merged, they just relax and consider the job done, so most likely linux-distros isn't even contacted at this point.
Open in Who Shared Issue with article?

BIO Attempts to Shift Drug Prices Conversation

|
By Ernie Smith Verified, A Subject
| Associations Now Verified
For years, the pharmaceutical industry has been dogged by complaints about high prices for its life-saving products, such as Daraprim and EpiPens. That complaint is a hard one to combat, but the Biotechnology Innovation Organization is ready to try. This week, BIO launched a new ad campaign, “Innovation Saves,” to highlight the value of innovation in the biopharmaceutical space. Its point? The drugs may not be cheap, but they’re very much worth the price.
Open in Who Shared Issue with article?
Show More